- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07813507
Precision Modulation of Gut Microbiome Enteropathogen Colonization in Critical Illness (MicroMod)
Phase 1b Randomized Controlled Trial Evaluating Medical Food Synbiotic KB-101+KB-102 for Safety and Dietary Management of Enteropathogen Colonization of the Gut Microbiome of Critically Ill Patients
Patients requiring life support therapies in intensive care units are at very high risk of hospital-acquired infections. An important source of these infections is the accumulation of pathogenic bacteria in the microbiome of their gut. We hypothesize that treatment with an enteral synbiotic (combination of probiotic and prebiotic), which has been specifically designed to combat pathogen colonization in the gastrointestinal tract, will be safe and effective to reduce pathogen levels in the gut, and potentially reduce infections.
We are conducting a phase 1b randomized, open-label, controlled trial to assess safety biological efficacy of enteral synbiotic therapy to reduce gastrointestinal enteropathogen colonization in adult critically ill patients.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Enteropathogen colonization of the gut microbiome in critically ill patients is associated with adverse outcomes. Observational studies have consistently reported that gut colonization with enteropathogens including Enterobacterales (e.g. Klebsiella spp., E. coli, Enterobacter spp., and others) and Enterococcus spp. (e.g. E. faecium) is associated with increased risks of hospital-acquired infections, death, organ dysfunction severity, prolongation of life support, and hospitalization. Mechanistically, gut enteropathogen colonization has been shown to contribute to adverse outcomes like hospital-acquired infections (HAI) through the gut's ability to serve as both a reservoir of HAI pathogens, as well as through pathological microbiome-immune interactions that suppress immune defences against HAI. Consequently, therapeutic strategies to reduce gut enteropathogen colonization have been identified as potentially impactful interventions to reduce hospital-acquired infections and adverse outcomes in patients with critical illness.
Prior clinical trials have employed diverse strategies to modulate the gut microbiome with the objective of reducing adverse outcomes, including large randomized controlled trials of probiotics, or opposing strategies such as digestive decontamination. However, outcomes have been heterogeneous owing to a number of crucial methodological limitations of both the interventions as well as study designs. First, despite proposed mechanisms involving microbiome modulation, none of the important trials have actually analyzed the microbiome to confirm whether their intervention favourably modified the microbiome (i.e. lack of confirmation of biological plausibility). Next, investigations of probiotics have suffered from a lack of rationalized designed for their intended mechanism. For example, the large RCT of probiotics in critically ill patients utilized Lactobacillus rhamnosus GG, yet the choice of this particular probiotic was not based on any prior mechanistic data demonstrating that this species could engraft in the ICU microbiome, nor whether it has the potential to displace enteropathogens from the gut. In fact, very few probiotic trials have ever even determined whether the probiotic strain could engraft into the ICU gut microbiome, nor have any trials determined whether interventions successfully decolonized enteropathogens.
To address these limitations, we will conduct a randomized controlled trial to assess both the safety and biological efficacy (microbiome engraftment and enteropathogen decolonization) of the synbiotic medical nutrition product in critically ill patients. In this phase 1b randomized controlled trial, 64 critically ill patients requiring mechanical ventilation will be randomly assigned to a 21-day course of enteral synbiotic or control (open label). Primary outcome will be safety and biological efficacy of synbiotic engraftment in the gut, with secondary outcome of gut enteropathogen colonization.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Braedon McDonald, MD, PhD, FRCPC
- Telefonnummer: 1-403-220-6885
- E-post: bamcdona@ucalgary.ca
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N1
- Foothills Medical Centre
-
Ta kontakt med:
- Braedon McDonald, MD, PhD, FRCPC
- Telefonnummer: 1-403-220-6885
- E-post: bamcdona@ucalgary.ca
-
Hovedetterforsker:
- Braedon McDonald, MD, PhD, FRCPC
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Adult (>18 years old) admitted to FMC ICU within 48h of admission
- Mechanically ventilated via endotracheal tube
- Expected duration of mechanical ventilation >72 hours from time of screening (as determined by attending ICU physician)
Exclusion Criteria:
- Goals of care designation that limits the use of life-sustaining interventions
- Life expectancy <72 hours (in the opinion of the attending ICU physician)
- Unable to receive enteral administration of medications
- Presence of ileus, discontinuous GI tract (including ileostomy), total or partial colectomy, bariatric surgery, inflammatory bowel disease, active graft-versus-host disease, cirrhosis with Child-Pugh Class C, or short bowel syndrome
- Acute immunosuppression including recent (within 30 days) cytotoxic chemotherapy; chronic systemic steroids (≥20 mg prednisone equivalent/day for >3 weeks); uncontrolled HIV infection (with CD4 count <400/μl); neutropenia (absolute neutrophil count <500/μL)
- Pregnancy or breastfeeding
- Concurrently taking pre-, pro-, synbiotic, or live biotherapeutic product, or other fermented food product and unwilling to discontinue these for the duration of the study
- Concurrently enrolled in another clinical trial of pre-, pro-, synbiotic, or live biotherapeutic product, antimicrobial, or immune modulator therapy
- History of lactose allergy (lactose intolerance not exclusionary)
- Unsuitable for inclusion in study in the opinion of the attending physician or investigator
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Synbiotic treatment
|
Synbiotic medical nutrition product consisting of probiotic and prebiotic combination
|
|
Sham-komparator: Control
Standard of care
|
Standard of care without synbiotic treatment.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety - Product-related adverse event rates
Tidsramme: Enrolment to day 90
|
Product-related adverse event rates
|
Enrolment to day 90
|
|
Biological efficacy
Tidsramme: Enrolment to day 90
|
Magnitude of gut microbiome engraftment by synbiotic
|
Enrolment to day 90
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gut enteropathogen colonization
Tidsramme: Enrolment to day 90
|
Abundance of enteropathogens in the gut (fecal) microbiome
|
Enrolment to day 90
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Sykdomsattributter
- Infeksjoner
- Iatrogen sykdom
- Patologiske tilstander, tegn og symptomer
- Kritisk sykdom
- Kryssinfeksjon
- Health Services Administration
- Helsevesenets kvalitet, tilgang og evaluering
- Kvalitet på helsehjelpen
- Kosttilskudd
- Mat
- Kosthold, mat og ernæring
- Fysiologiske fenomener
- Mat og drikke
- Kvalitetsindikatorer, helsehjelp
- Prebiotika
- Probiotika
- Standard for omsorg
- Synbiotika
Andre studie-ID-numre
- REB26-0527
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .